4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada

4D Molecular Therapeutics (NASDAQ:FDMT) had its price target hoisted by research analysts at Royal Bank Of Canada from $32.00 to $35.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 294.99% from the company’s current price.

A number of other equities research analysts have also commented on FDMT. Barclays assumed coverage on 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $32.17.

4D Molecular Therapeutics Stock Up 3.5%

NASDAQ:FDMT traded up $0.30 on Thursday, reaching $8.86. The stock had a trading volume of 175,518 shares, compared to its average volume of 727,826. The company has a market capitalization of $506.23 million, a P/E ratio of -2.38 and a beta of 2.99. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34. The stock has a fifty day moving average price of $8.70 and a 200-day moving average price of $9.09.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Friday, March 20th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $85.09 million during the quarter, compared to analyst estimates of $30.86 million. Sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in FDMT. BVF Inc. IL grew its position in shares of 4D Molecular Therapeutics by 1.5% in the 2nd quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock valued at $17,175,000 after purchasing an additional 68,000 shares during the period. XTX Topco Ltd bought a new position in 4D Molecular Therapeutics in the second quarter valued at approximately $292,000. Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics in the second quarter valued at approximately $42,000. Dynamic Technology Lab Private Ltd increased its position in shares of 4D Molecular Therapeutics by 35.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company’s stock worth $61,000 after acquiring an additional 4,295 shares in the last quarter. Finally, Peapod Lane Capital LLC increased its position in shares of 4D Molecular Therapeutics by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 322,081 shares of the company’s stock worth $2,799,000 after acquiring an additional 3,544 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.